- Home
- MIRM vs MLYS Comparison
MIRM vs MLYS Comparison
Compare MIRM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MLYS
- Stock Information
- Founded
- MIRM 2018
- MLYS 2019
- Country
- MIRM United States
- MLYS United States
- Employees
- MIRM 349
- MLYS N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- MLYS Health Care
- Exchange
- MIRM Nasdaq
- MLYS Nasdaq
- Market Cap
- MIRM 3.7B
- MLYS 3.1B
- IPO Year
- MIRM 2019
- MLYS 2023
- Fundamental
- Price
- MIRM $72.85
- MLYS $37.69
- Analyst Decision
- MIRM Strong Buy
- MLYS Strong Buy
- Analyst Count
- MIRM 11
- MLYS 6
- Target Price
- MIRM $76.09
- MLYS $42.60
- AVG Volume (30 Days)
- MIRM 712.9K
- MLYS 1.5M
- Earning Date
- MIRM 11-11-2025
- MLYS 11-10-2025
- Dividend Yield
- MIRM N/A
- MLYS N/A
- EPS Growth
- MIRM N/A
- MLYS N/A
- EPS
- MIRM N/A
- MLYS N/A
- Revenue
- MIRM $429,161,000.00
- MLYS N/A
- Revenue This Year
- MIRM $53.14
- MLYS N/A
- Revenue Next Year
- MIRM $19.83
- MLYS N/A
- P/E Ratio
- MIRM N/A
- MLYS N/A
- Revenue Growth
- MIRM 62.33
- MLYS N/A
- 52 Week Low
- MIRM $36.88
- MLYS $8.24
- 52 Week High
- MIRM $78.10
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- MLYS 65.26
- Support Level
- MIRM $70.49
- MLYS $35.32
- Resistance Level
- MIRM $74.96
- MLYS $40.91
- Average True Range (ATR)
- MIRM 1.82
- MLYS 1.90
- MACD
- MIRM -0.72
- MLYS -0.93
- Stochastic Oscillator
- MIRM 51.03
- MLYS 48.31
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.